Free Trial

Tarsus Pharmaceuticals (TARS) Competitors

Tarsus Pharmaceuticals logo
$41.50 -0.94 (-2.21%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$41.52 +0.02 (+0.06%)
As of 07/25/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TARS vs. RGC, RVMD, GRFS, TGTX, NUVL, RYTM, CRSP, AXSM, TLX, and LNTH

Should you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Regencell Bioscience (RGC), Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

Tarsus Pharmaceuticals vs. Its Competitors

Tarsus Pharmaceuticals (NASDAQ:TARS) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Tarsus Pharmaceuticals has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Regencell Bioscience has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500.

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Regencell Bioscience has lower revenue, but higher earnings than Tarsus Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tarsus Pharmaceuticals$233.67M7.46-$115.55M-$2.73-15.20
Regencell BioscienceN/AN/A-$4.30MN/AN/A

Regencell Bioscience has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -44.91%. Regencell Bioscience's return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Tarsus Pharmaceuticals-44.91% -39.72% -25.74%
Regencell Bioscience N/A N/A N/A

Tarsus Pharmaceuticals presently has a consensus target price of $66.67, suggesting a potential upside of 60.64%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Tarsus Pharmaceuticals is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tarsus Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00
Regencell Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Tarsus Pharmaceuticals and Tarsus Pharmaceuticals both had 3 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 1.26 beat Regencell Bioscience's score of 1.19 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tarsus Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Regencell Bioscience
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Tarsus Pharmaceuticals beats Regencell Bioscience on 8 of the 13 factors compared between the two stocks.

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TARS vs. The Competition

MetricTarsus PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.74B$3.06B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E Ratio-15.2021.1828.1020.05
Price / Sales7.46288.62432.4890.19
Price / CashN/A42.7636.2258.56
Price / Book7.078.378.665.87
Net Income-$115.55M-$55.19M$3.25B$258.55M
7 Day Performance-4.05%5.88%4.22%3.73%
1 Month Performance2.90%17.33%10.51%11.75%
1 Year Performance65.93%4.42%34.40%18.03%

Tarsus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TARS
Tarsus Pharmaceuticals
1.5333 of 5 stars
$41.50
-2.2%
$66.67
+60.6%
+47.0%$1.74B$233.67M-15.2050Positive News
RGC
Regencell Bioscience
0.2394 of 5 stars
$14.40
-0.7%
N/AN/A$7.17BN/A0.0010Positive News
RVMD
Revolution Medicines
4.4972 of 5 stars
$38.42
+0.3%
$68.91
+79.4%
-16.8%$7.13B$11.58M-9.61250News Coverage
GRFS
Grifols
3.317 of 5 stars
$10.00
+0.6%
$10.30
+3.0%
+29.8%$6.83B$7.81B8.5523,822Positive News
Upcoming Earnings
TGTX
TG Therapeutics
3.7099 of 5 stars
$37.42
-1.3%
$43.80
+17.0%
+84.7%$6.02B$329M157.96290Positive News
NUVL
Nuvalent
3.203 of 5 stars
$82.46
-1.1%
$119.60
+45.0%
+1.8%$5.99BN/A-18.7840
RYTM
Rhythm Pharmaceuticals
3.128 of 5 stars
$88.63
-0.6%
$91.93
+3.7%
+74.3%$5.68B$130.13M-31.54140Analyst Upgrade
CRSP
CRISPR Therapeutics
2.5448 of 5 stars
$65.33
+0.3%
$71.75
+9.8%
+12.5%$5.62B$37.31M-14.45460Analyst Forecast
High Trading Volume
AXSM
Axsome Therapeutics
4.744 of 5 stars
$109.68
-1.8%
$172.33
+57.1%
+17.3%$5.50B$385.69M-19.01380News Coverage
Positive News
Analyst Revision
TLX
Telix Pharmaceuticals
N/A$16.50
+1.7%
$22.33
+35.4%
N/A$5.49B$516.72M0.00N/ANews Coverage
Analyst Revision
High Trading Volume
LNTH
Lantheus
4.7056 of 5 stars
$71.56
+2.0%
$131.20
+83.3%
-35.4%$4.86B$1.53B20.33700Positive News

Related Companies and Tools


This page (NASDAQ:TARS) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners